Optimizing thiopurine therapy in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 6, 2011, Pages 1428-1435

  Chevaux, Jean Baptiste ^a   Peyrin Biroulet, Laurent ^a   Sparrow, Miles P ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b ALFRED HOSPITAL   (Australia)

Author keywords

inflammatory bowel disease; optimization; thiopurines

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENTERITIS; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

6-MERCAPTOPURINE; AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES;

EID: 79955820771     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21494     Document Type: Review

References (64)

1. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940-987. (Pubitemid 43374543)
2. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis. 2010; 4: 28-62.
3. Travis S, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis. 2008; 2: 24-62. (Pubitemid 351179488)
4. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008; 372: 67-81. (Pubitemid 351902263)
5. Schwartz M, Cohen R,. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008; 10: 585-590.
6. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database System Rev. 2009:CD000067.
7. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009; 30: 126-137.
8. Cassinotti A, Travis S., Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009; 15: 1264-1275.
9. Derijks LJ, Wong DR., Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des. 2010; 16: 145-154.
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000; 118: 705-713. (Pubitemid 30171620)
11. Weinshilboum RM, Sladek SL., Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32: 651-662. (Pubitemid 10061685)
12. Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J. 2005; 35: 580-585. (Pubitemid 41564403)
13. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999; 9: 37-42. (Pubitemid 29176722)
14. Roberts RL, Gearry RB, Bland MV, et al. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics. 2008; 18: 434-438. (Pubitemid 351535944)
15. Lennard L., The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43: 329-339.
16. Gardiner SJ, Gearry RB, Barclay ML, et al. Two cases of thiopurine methyltransferase (TPMT) deficiencyâa lucky save and a near miss with azathioprine. Br J Clin Pharmacol. 2006; 62: 473-476. (Pubitemid 44401530)
17. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118: 1025-1030. (Pubitemid 30346978)
18. Gardiner SJ, Gearry RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008; 6: 654-660.
19. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 973-983.
20. Wong DR, Derijks LJ, den Dulk MO, et al. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther Drug Monit. 2007; 29: 845-848. (Pubitemid 350190865)
21. Kudo M, Moteki T, Sasaki T, et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics. 2008; 18: 243-251. (Pubitemid 351323239)
22. Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009; 30: 375-384.
23. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004; 14: 181-187. (Pubitemid 38373112)
24. Gearry RB, Roberts RL, Barclay ML, et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 2004; 14: 779-781. (Pubitemid 39552794)
25. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008; 66: 517-528.
26. Gearry RB, Barclay ML., Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005; 20: 1149-1157. (Pubitemid 41602556)
27. Hindorf, U, Lindqvist, M, Peterson, C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55: 1423-1431. (Pubitemid 44476786)
28. Sparrow, MP, Irving, PM, Hanauer, SB,. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009; 11: 496-503.
29. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007; 26: 217-225. (Pubitemid 46985496)
30. Mantzaris GJ, Roussos A, Kalantzis C, et al. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission ? Inflamm Bowel Dis. 2007; 13: 446-450. (Pubitemid 46668250)
31. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130: 1047-1053.
32. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001; 49: 665-670. (Pubitemid 32989203)
33. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001; 36: 71-76. (Pubitemid 32147184)
34. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-Thioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther. 2005; 21: 829-839. (Pubitemid 40477243)
35. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122: 904-915. (Pubitemid 34267273)
36. Reinshagen M, Schutz E, Armstrong VW, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007; 53: 1306-1314. (Pubitemid 47020987)
37. Dassopoulos T, Martin CF, Galanko J, et al. T1192 A randomized trial of metabolite-adjusted versus weight-based dosing of azathioprine in Crohn's disease. [Clinicaltrials.Gov Identifier Nct00113503]. Gastroenterology. 2009; 136:A-519.
38. Szumlanski CL, Weinshilboum RM., Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995; 39: 456-459.
39. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006; 12: 251-257.
40. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007; 102: 2747-2753. (Pubitemid 350179331)
41. Daperno M, Sostegni R, Canaparo R, et al. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2009; 30: 843-853.
42. Elion GB, Kovensky A, Hitchings GH., Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966; 15: 863-880.
43. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet. 1993; 342: 83-84. (Pubitemid 23192425)
44. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005; 22: 441-446. (Pubitemid 41248111)
45. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007; 5: 209-214. (Pubitemid 46216945)
46. Leung Yea,. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohn's Colitis. 2009; 3: 162-167.
47. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 734-741.
48. Rahhal RM, Bishop WP., Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1678-1682.
49. Witte TN, Ginsberg AL., Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol. 2008; 22: 181-185.
50. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 31: 640-647.
51. Nguyen TM, Le Gall C, Lachaux A, et al. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease pediatric patients receiving aminosalicylates combined with azathioprine. Int J Clin Pharmacol Ther. 2010; 48: 275-281.
52. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007; 56: 1404-1409. (Pubitemid 47517834)
53. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003; 125: 298-303. (Pubitemid 36929408)
54. Sokol H, Beaugerie L., Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009; 58: 1427-1436.
55. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000; 47: 514-519.
56. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16: 1225-1232.
57. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125. (Pubitemid 41025906)
58. Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol. 2000; 24: 66-73. (Pubitemid 30033398)
59. Wong NA, Herbst H, Herrmann K, et al. Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas. J Pathol. 2003; 201: 312-318. (Pubitemid 37264910)
60. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374: 1617-1625.
61. Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 32: 119-130.
62. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
63. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508.
64. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.